Hayato Mizuta

Yokohama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts.

AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts.

Journal: Cancer science

Published: October 30, 2024

Identification of C-mannosylation in a receptor tyrosine kinase AXL.

Identification of C-mannosylation in a receptor tyrosine kinase AXL.

Journal: Glycobiology

Published: March 26, 2024

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.

Journal: Cancer discovery

Published: February 17, 2024

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer.

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer.

Journal: NPJ precision oncology

Published: September 07, 2023

DPY19L3 promotes vasculogenic mimicry by its C-mannosyltransferase activity.

DPY19L3 promotes vasculogenic mimicry by its C-mannosyltransferase activity.

Journal: Oncology research

Published: March 30, 2023

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.

Journal: Cancer discovery

Published: December 23, 2022

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes.

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes.

Journal: NPJ precision oncology

Published: December 08, 2022

C-mannosylation regulates stabilization of RAMP1 protein and RAMP1-mediated cell migration.

C-mannosylation regulates stabilization of RAMP1 protein and RAMP1-mediated cell migration.

Journal: The FEBS journal

Published: April 20, 2022

Requirement for C-mannosylation to be secreted and activated a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4).

Requirement for C-mannosylation to be secreted and activated a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4).

Journal: Biochimica et biophysica acta. General subjects

Published: October 12, 2020

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.

Journal: Nature communications

Published: May 14, 2020

The fibrinogen C-terminal domain is seldom C-mannosylated but its C-mannosylation is important for the secretion of microfibril-associated glycoprotein 4.

The fibrinogen C-terminal domain is seldom C-mannosylated but its C-mannosylation is important for the secretion of microfibril-associated glycoprotein 4.

Journal: Biochimica et biophysica acta. General subjects

Published: October 07, 2019

C‑mannosylation of R‑spondin2 activates Wnt/β‑catenin signaling and migration activity in human tumor cells.

C‑mannosylation of R‑spondin2 activates Wnt/β‑catenin signaling and migration activity in human tumor cells.

Journal: International journal of oncology

Published: November 05, 2018

Showing 1-12 of 12

Last Updated: 09/26/2026